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Abstract  
Background: Recent studies have called into question the long-held belief that hysterectomy 
without oophorectomy protects against ovarian cancer. This population-based longitudinal 
record-linkage study aimed to explore this relationship, overall and by age at hysterectomy, 
time period, surgery type, and indication for hysterectomy. 
Methods: We followed the female adult Western Australian population (837,942 women) 
across a 27-year period using linked electoral, hospital, births, deaths, and cancer records. 
Surgery dates were determined from hospital records, and ovarian cancer diagnoses (n=1,640) 
were ascertained from cancer registry records. We used Cox regression to estimate hazard 
ratios (HRs) and 95% confidence intervals (CIs) for the association between hysterectomy and 
ovarian cancer incidence.  
Results: Hysterectomy without oophorectomy (n=78,594) was not associated with risk of 
invasive ovarian cancer overall (HR = 0.98, 95% CI = 0.85-1.11), or with the most common 
serous subtype (HR = 1.05, 95% CI = 0.89-1.23). Estimates did not vary statistically 
significantly by age at procedure, time period or surgical approach. However, among women 
with endometriosis (5.8%) or with fibroids (5.7%), hysterectomy was associated with 
substantially decreased ovarian cancer risk, overall (HR = 0.17, 95% CI = 0.12-0.24 and HR = 
0.27, 95% CI = 0.20-0.36, respectively) and across all subtypes.  
Conclusions: Our results suggest that for most women, having a hysterectomy with ovarian 
conservation is not likely to substantially alter their risk of developing ovarian cancer. 
However, our results, if confirmed, suggest that ovarian cancer risk reduction could be 
considered as a possible benefit of hysterectomy when making decisions about surgical 
management of endometriosis or fibroids. 
Keywords: ovarian cancer, hysterectomy, record-linkage, endometriosis, fibroids  
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Introduction 
Hysterectomy without oophorectomy has been traditionally considered protective against 
ovarian cancer, supported by a considerable body of older research (summarized in (1-3)). 
However, many studies including women diagnosed more recently have not seen a protective 
association; indeed, some reported modest increases in risk, as seen in a recent meta-analysis 
(4) and subsequent studies (5, 6). This apparent shift could arise from changing surgical 
practices or patient characteristics, changes in menopausal hormone therapy (MHT) use, or 
perhaps improved reporting of oophorectomy status.  
Hysterectomy is one of the most common major surgeries among women globally (7, 8); 
understanding the true relationship between hysterectomy alone and ovarian cancer risk is 
important to inform the current debate over the relative advantages of prophylactically 
removing ovaries at hysterectomy. Our aim was to explore the association between 
hysterectomy for benign indications and ovarian cancer risk, overall and by time period, age 
at surgery, hysterectomy type, and indication for hysterectomy. We examined this question 
using 45 years of administrative data from the Western Australian Data Linkage System 
(WADLS) (9).  
 
Methods 
Study population and linkage 
We conducted a retrospective cohort study including all women on the Western 
Australian (WA) Electoral Roll (enrollment to vote is compulsory) when electronic records 
began in 1988, or who registered subsequently. We restricted the cohort to women aged ≤45 
years in 1975, when hysterectomy began to be reliably recorded, to minimize inclusion of 
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women who had hysterectomies, oophorectomies, or cancer diagnoses before observation. 
Women born from 1930 to 1998 (the last birth-year for which women would reach electoral 
enrollment age within our observation period) were therefore eligible for the analysis. This 
cohort was linked with the WA Hospital Morbidity Data Collection (HMDC; 1970-2014), 
WA Cancer Registry (1982-2015), Midwives Notifications System (MNS; 1980-2013), and 
WA Births (1950-1979) and Deaths (1988-2015) Registers, allowing follow-up from 1988 
until mid-2015. The Western Australian Data Linkage Branch linked the datasets using 
probabilistic linkage matching on identifying and demographic fields and provided de-
identified data to the researchers. We excluded women with: recorded ovarian cancer, 
oophorectomy, or hysterectomy for malignancy before their first electoral record (n=9805); 
or data inconsistencies (implausible birthdates, births after hysterectomy, first electoral record 
after death, or male-specific codes: n=1313). 
The study received approval from QIMR Berghofer and WA Health Human Research 
Ethics Committees. 
Variable measurement 
Our main outcome was diagnosis of primary invasive epithelial cancer in the ovary 
(International Classification of Diseases [ICD]-10 code C56), fallopian tube (C57.0) or 
peritoneum (C48), recorded in the WA Cancer Registry, hereafter referred to collectively as 
‘ovarian cancer’. Available data included date/basis of diagnosis, and tumor site, behavior, 
grade, and morphology. Using morphology ICDO-3 codes we classified cancers as serous, 
mucinous, endometrioid, clear cell, or other. 
The HMDC contains information on all public and private WA hospital separations, 
including admission/discharge month and year, diagnosis codes (principal, 21 additional), 
and surgical procedure codes (principal, 10 additional) (see Supplementary Tables 1 and 2 
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for codes). We used procedure codes to ascertain hysterectomies, oophorectomies, and tubal 
ligations, and diagnosis codes to identify hysterectomy indications and ovarian cancer 
diagnoses before cancer registry records began. 
Birth-year (from electoral records) was provided in 5-year bands to protect anonymity; 
we derived age by assigning birthdate as the lowermost end. Electoral records include 
postcode, from which we derived remoteness of residence (major cities/inner regional/outer 
regional/remote/very remote) using the Accessibility and Remoteness Index of Australia 
(ARIA+) (10, 11), and socio-economic disadvantage quintiles using the Socio-Economic 
Indexes for Areas (SEIFA) (12), at study entry. We determined parity using the Births 
Register and MNS, assuming nulliparity at 1950 for women (n=68,218) who reached 
reproductive age before records began. 
Statistical analysis 
We calculated person-time for each woman as the interval between study entry (her first 
appearance in the available electoral records) and exit, determined as the earliest of: ovarian 
cancer diagnosis; hysterectomy or unilateral/bilateral oophorectomy if followed within 6 
months by ovarian cancer diagnosis (surgery date was then assigned as diagnosis date, as we 
considered these surgeries were likely related to their cancer); or a censoring condition, at 
which follow-up ceased. Censoring conditions were: all other unilateral/bilateral 
oophorectomies (including at hysterectomy); hysterectomy for other malignancies 
(predominantly endometrial); diagnosis of non-epithelial ovarian cancer; death; emigration; 
or end of observation (30/06/2015). We calculated exposed and unexposed person-time 
considering hysterectomy, parity, and tubal ligation as time-varying using the counting 
process method (13). Thus person-time from entry until hysterectomy (or until exit, for 
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unexposed women) was considered unexposed; any observed time after hysterectomy (from 
study entry, for women with prior hysterectomies) was considered exposed. 
We performed Cox proportional-hazards regression, estimating hazard ratios (HRs) and 
95% confidence intervals (CI) for the association between hysterectomy and ovarian cancer 
incidence, overall and for different histologic subtypes, using age as the underlying time scale 
(14). We stratified models by birth decade, and adjusted for age at entry, parity (≥3 vs 0-2 
births), and tubal ligation (yes/no). We omitted SEIFA and ARIA from final models because 
they did not change HRs for the main association. The proportional hazards assumption was 
confirmed graphically by plotting Schoenfeld residuals against time.  
We conducted additional analyses comparing risk associated with hysterectomy 
performed in three eras (<1990, 1990-2002, >2002). Time periods were chosen based on 
trends in MHT use, which may influence the association (15). MHT use decreased in the 
1970s then increased again (1980s), became widespread during the 1990s, then declined 
sharply from 2002 (16), when Women's Health Initiative investigators reported that 
combined MHT use was associated with adverse health outcomes (17). We examined 
whether the association varied by age (as a proxy for menopausal status) at hysterectomy, 
considering <45 (mostly premenopausal women), 45-54 (peri-menopausal women), and ≥55 
years (mostly post-menopausal women). We compared risk associated with abdominal or 
vaginal hysterectomy (numbers were insufficient to examine solely laparoscopic 
hysterectomy). Lastly, we performed analyses considering hysterectomy indication, focusing 
on three common indications (endometriosis, uterine leiomyoma [fibroids], and genital 
prolapse). 
We conducted sensitivity analyses, including: varying elements of the methods (using 
years as the time-scale); varying the population (to women <45 years when hospital [1970] or 
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cancer registry [1982] records began, vs. applying no age restriction; excluding women 
entering after 1988 after usual enrollment age [>25 years; therefore women migrating into 
WA]; examining associations by birth cohort); selecting different comparison groups 
(estimating associations for later vs. earlier hysterectomies in age/period analyses); and 
restricting the outcome to cancer of the ovary (censoring at fallopian tube/peritoneal cancer 
diagnosis). 
Analyses were performed in SAS 9.4 (SAS Institute Inc., N.C.). Tests of statistical 
significance were two-sided and we used an alpha level of 5% to determine statistical 
significance; to determine the statistical significance of the hazard ratios in our analysis, we 
assessed whether the 95% CI crossed 1.00. 
 
Results 
We included 837,942 women (aged 17-82 [median 30] years at entry, 17-87 [median 50] 
at exit) contributing 15,738,607 person-years of follow-up. The cohort included 223,049 
women (26.6%) who entered in 1988 (median age at entry/exit 38/65) and 614,893 women 
(73.4%) who entered later (median age at entry/exit 26/45). Overall 78,594 women had a 
recorded hysterectomy for a benign indication before study exit (28,091 occurred before 
entry) and contributed 1,335,989 exposed person-years. There were 81,927 tubal ligations 
before exit. At their study entry, 715,329 (85.4%) of women had 0-2 children and 122,613 
(14.6%) had 3 or more; by study exit, 610,857 (72.9%) had 0-2 children, and 227,085 
(27.1%) had 3 or more. At entry, 622,446 (74.3%) lived in major cities, 147,874 (17.6%) in 
inner/outer regional and 60,228 (7.2%) in remote/very remote areas; 31.3% were in the least 
and 16.9% in the most disadvantaged SEIFA quintile. There were 48,870 (5.8%) women with 
a diagnosis of endometriosis (most at hysterectomy), 47,407 (5.7%) with fibroids (15,037 had 
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both conditions), and 55,752 (6.7%) with prolapse. During the study window 1,640 women 
were diagnosed with invasive epithelial ovarian cancer (including 1020 serous, 125 
mucinous, 146 endometrioid, and 90 clear cell cancers). Table 1 presents population 
characteristics by hysterectomy/exposure status. 
Hysterectomy was not associated with decreased risk of invasive epithelial ovarian 
cancer overall (HR 0.98, 95%CI 0.85-1.11), or for the most common serous subtype (HR 
1.05, 95%CI 0.89-1.23), after adjusting for age, tubal ligation, and parity. Effect estimates 
were in the protective direction for mucinous (HR 0.55, 95%CI 0.28-1.06), endometrioid (HR 
0.69, 95%CI 0.41-1.18) and clear cell (HR 0.56, 95%CI 0.27-1.16) tumors, but were not 
statistically significant (Table 2).  
Analyses by time period (Figure 1A) showed no association with ovarian cancer overall 
for hysterectomies performed <1990 (HR 0.93, 95%CI 0.79-1.10), and a slightly positive but 
statistically nonsignificant association for hysterectomies performed 1990-2002 (HR 1.14, 
95%CI 0.93-1.40). The association for hysterectomies performed >2002 was inverse (HR 
0.60, 95%CI 0.34-1.06), although not statistically significant. The association did not vary 
substantively by age at hysterectomy: <45 years, HR 0.94 (95%CI 0.77-1.15); 45-55 years, 
HR 1.01 (95%CI 0.84-1.21); >55 years, HR 0.96 (95%CI 0.68-1.34) (Figure 1B). Results by 
type of hysterectomy are presented in Supplementary Table 3. There were too few cancers 
to conduct period, age, or surgical type analyses by histologic subtype. 
Our two a priori approaches to assess whether the association varied by indication were: 
first, to adjust the main models for the indication(s) for hysterectomy; and second, to examine 
in a separate model the association between hysterectomy for each indication coded at 
surgery (a single multi-level variable) and risk, compared to no hysterectomy. Implementing 
the first approach, we observed that after adjusting models for ever-diagnosis of 
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endometriosis or fibroids, estimates of the association decreased for ovarian cancer overall 
(HR 0.65, 95%CI 0.56-0.75), and for each subtype (serous HR 0.76 [95%CI 0.63-0.91], 
mucinous HR 0.38, 95%CI 0.19-0.75; endometrioid HR 0.30, 95%CI 0.17-0.52; clear cell 
HR 0.19, 95%CI 0.09-0.41) (Table 2). Further adjustment for prolapse did not substantially 
alter effect estimates.  
Implementing our second approach, we constructed a model estimating risk associated 
with hysterectomy performed for each indication. We observed that, compared to women 
without hysterectomy (which includes women with/without diagnosis of each indication), 
estimates were in the direction of slightly increased ovarian cancer risk for hysterectomy for 
endometriosis (without fibroids/prolapse) (HR 1.18, 95%CI 0.71-1.96), or fibroids (without 
endometriosis/prolapse) (HR 1.10, 95%CI 0.79-1.55), and apparent slight decreased ovarian 
cancer risk for hysterectomy for prolapse (without endometriosis/fibroids) (HR 0.89, 95%CI 
0.67-1.18), although none were statistically significant (Table 3). However, these conditions 
were associated with ovarian cancer risk irrespective of hysterectomy. Ever-diagnosis of 
endometriosis was associated with increased ovarian cancer risk (HR 2.74, 95%CI 2.32-
3.22), with particularly strong associations for endometrioid (HR 7.42, 95%CI 4.80-11.48) 
and clear cell (HR 12.24, 95%CI 7.23-20.73) cancers (Supplementary Table 4). Ever-
diagnosis of fibroids was associated with increased risk overall (HR 1.97, 95%CI 1.69-2.30), 
with little variation by subtype (Supplementary Table 4). Ever-diagnosis of prolapse was 
associated with decreased risk overall (HR 0.68, 95%CI 0.57-0.80), with little variation by 
subtype except a stronger inverse association for clear cell cancers (HR 0.38, 95%CI 0.16-
0.89) (Supplementary Table 4). 
To distinguish the effect of hysterectomy for a particular indication from the effect of the 
condition itself, we implemented a third approach, stratifying by each condition and repeating 
our analysis within those strata. We observed that among women ever diagnosed with 
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endometriosis, hysterectomy was associated with substantially decreased ovarian cancer risk 
(HR 0.17, 95%CI 0.12-0.24, overall) (Table 4), with fairly consistent HRs across subtypes 
(Supplementary Table 5). Similarly, hysterectomy was associated with decreased risk 
among women with fibroids (HR 0.27, 95%CI 0.20-0.36 overall) (Table 4), which again was 
similar across subtypes (Supplementary Table 5). The strong inverse relationship among 
women with endometriosis or fibroids remained, although was slightly attenuated, after 
excluding women with the other condition (data not shown). Among women without 
endometriosis, without fibroids, and with neither condition, there was no protective effect of 
hysterectomy (for example, HR 1.15, 95%CI 0.98-1.35, overall, among women with neither 
condition) (Table 4). In women with prolapse, the effect estimate was slightly elevated but 
not statistically significant (HR 1.24, 95%CI 0.91-1.69) (Table 4). 
Our results were robust to the method used to estimate person-years. Including older 
women (relaxing/removing the age restriction) yielded similar estimates although some 
became slightly inverse (Supplementary Table 6), consistent with the hypothesis that 
including older women increases misclassification of women with prior oophorectomy. 
Restricting analyses to younger women (<45 in 1982), or excluding women migrating into 
WA, made little difference to estimates (Supplementary Table 6). There were no obvious 
patterns by birth cohort, although numbers were generally too low to draw clear conclusions. 
Estimates were similar when we repeated analyses defining outcome strictly as cancer of the 
ovary (ICD code C56), except for a stronger inverse association for mucinous cancers (data 
not shown). 
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Discussion 
In this large retrospective study using linked administrative data we found that 
hysterectomy was not associated with decreased ovarian cancer risk either overall or for the 
most common and aggressive form (serous cancer), and that reductions in risk were not 
observed in earlier time periods. There was a suggestion of decreased risk of non-serous 
ovarian cancers which was not statistically significant. The association varied minimally by 
age at surgery or type of hysterectomy. Among women with endometriosis or fibroids, two 
common indications for this procedure, hysterectomy was associated with substantially 
decreased ovarian cancer risk. 
While older studies had suggested a protective effect of hysterectomy on ovarian cancer 
(18, 19), almost all recent studies have not shown this (20, 21). Our results are consistent with 
recent findings; we did not see inverse associations even for hysterectomies performed in the 
1970s/1980s. The discrepancy between older and newer studies may arise from better self-
reporting of oophorectomy. Many women with documented bilateral oophorectomy report 
that their ovaries have not been removed (22). It may be that women in older studies, with 
hysterectomies undertaken further back in time, were less likely to be aware that 
oophorectomy had been simultaneously performed. Our study avoids this bias by ascertaining 
oophorectomy using hospital records. 
Fluctuations in MHT use may have also influenced associations over time. MHT is 
prescribed more frequently to women with hysterectomy than those without, and is associated 
with modestly increased ovarian cancer risk (23). Two large studies have reported that 
hysterectomy is associated with slightly increased ovarian cancer risk among ever-users of 
MHT, but decreased risk among never-users (24, 25). Without data on MHT use we could not 
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directly explore its influence, but the slight increased risk associated with hysterectomies in 
the 1990s, when MHT was common, and reduced risk thereafter, when MHT use fell, is 
consistent with this pattern. However, we had short follow-up and few hysterectomies and 
cancer diagnoses after 2002. 
Some previous studies have suggested that hysterectomy at younger ages particularly 
(<45 or <50) may be associated with reduced ovarian cancer risk (4). However, we found 
little variation in the association by surgery age.  
We found some evidence that the association varies by histologic subtype, with no 
association seen for serous cancers but a suggestion of inverse relationships with non-serous 
tumors, particularly mucinous and clear cell. These results closely match subtype-specific 
estimates from a recent pooled analysis of 21 cohorts (6). Some (5, 26-28), but not all (29, 
30), large case-control studies have also reported risk reductions for non-serous tumors. 
A novel finding of our study was that hysterectomy appeared to substantially reduce risk 
among women with endometriosis or fibroids (both of which were associated with 
considerably increased ovarian cancer risk in our population). Few studies have considered 
indication for hysterectomy. One case-control study reported that adjustment for 
endometriosis, fibroids, and ovarian cysts decreased the odds ratio for the 
hysterectomy/ovarian cancer association (24), as we found. An analysis pooling four case-
control studies (2098 cases) compared women with/without endometriosis and, consistent 
with our results, reported that hysterectomy was associated with possible decreased ovarian 
cancer risk among women with endometriosis (OR 0.69, 95%CI 0.38-1.24) but not without 
(OR 1.02, 95%CI 0.86-1.23) (31). Use of self-reported endometriosis, consequently including 
a broader disease spectrum with more misclassification, may explain their weaker 
association, as self-reported endometriosis is associated with lower ovarian cancer risk than 
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surgically confirmed endometriosis (32). Another study of women with endometriosis found 
that removal of endometriotic lesions substantially reduced ovarian cancer risk, while 
hysterectomy did not (33). It is possible that the protective effect we observed is primarily 
due to simultaneous removal of lesions. Fibroids have rarely been assessed in relation to 
ovarian cancer. One Danish record-linkage study reported that women with fibroids are at 
increased risk of ovarian cancer (RR 1.36, 95%CI 1.16-1.60), particularly endometrioid 
tumors (RR 1.57, 95%CI 1.05-2.34) (34), a similar although slightly weaker association than 
we observed. We know of no studies examining the hysterectomy/ovarian cancer relationship 
by the presence/absence of fibroids. Our findings among women with these conditions, while 
intriguing and plausible, were obtained from post-hoc subgroup analyses and require 
replication. 
Notable strengths of our study include its large size, population-based design, long-term 
follow-up, and measurement of exposure and outcome using medical records. Compulsory 
electoral enrollment allowed us to include virtually all female WA residents. Ascertaining 
hysterectomy/oophorectomy status using hospital data eliminates recall error, a concern in 
many previous studies. Misclassification of hysterectomy status is likely to be minimal, since: 
the HMDC records all surgeries in WA; residents infrequently receive care elsewhere due to 
geographic isolation (35); we restricted the analysis to younger women at the start of hospital 
records; and excluding women migrating into WA during observation did not change our 
findings. Precise information on surgery date allowed accurate classification of exposed time. 
Reporting diagnoses of malignant solid tumors to the cancer registry is mandatory, so most 
ovarian cancers after 1982 should be captured. 
Our study is not without limitations. We may not have captured exposures or outcomes 
occurring prior to available hospital records. We mitigated this by restricting to women aged 
≤45 years in 1975 (the start of reliable hysterectomy data). Residual misclassification 
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resulting from unrecorded early hysterectomies (perhaps chiefly among 6.7% of women 
without recorded hysterectomy, who entered in 1988 and were aged 30-45 in 1975) would 
have reduced the difference between exposed and unexposed groups, attenuating any 
association. However, restricting our analysis to younger women resulted in similar 
estimates, suggesting that misclassification was minimal. Our study design limited access to 
information on some possible confounding factors, which are not usually recorded in 
administrative data sources. However, the confounders we were able to include had 
negligible influence on our effect estimates, and confounders which were unrecorded would 
be expected to have modest effects (for instance, oral-contraceptive use is not strongly related 
to hysterectomy [for example, (36)]). For the same reason we could not directly assess the 
effect of any changes in MHT use over time. We compared the association between time-
periods chosen to reflect different levels of MHT use, and observed suggestive differences. 
MHT use is only moderately associated with ovarian cancer risk (23) but could account for a 
portion of the difference. Future studies examining this association should incorporate MHT 
use if possible. 
In summary, we conducted a large, population-based record-linkage study using up to 45 
years of data for women in Western Australia. Our results for women with endometriosis and 
fibroids require replication, but suggest that hysterectomy may reduce ovarian cancer risk 
among these women. However, women without these conditions should not be advised that 
hysterectomy alone will reduce their ovarian cancer risk.  
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Table 1: Demographic and reproductive characteristics of included women, by final hysterectomy status recorded 1970-2015  
Characteristic 
No hysterectomy 
(N=733,832) 
Hysterectomy contributing 
exposed time* (N=78,594) 
Hysterectomy contributing no 
exposed time † (N=25,516) 
No. (%) No. (%) No. (%) 
Age at study entry, y    
<30 385,380 (52.5) 12,054 (15.3) 5,428 (21.3) 
30-<40 159,300 (21.7) 23,759 (30.2) 7,840 (30.7) 
40-<50 107,808 (14.7) 26,584 (33.8) 8,159 (32.0) 
50-<60 66,378 (9.0) 14,794 (18.8) 3,690 (14.5) 
60-<70 12,870 (1.8) 1,331 (1.7) 373 (1.5) 
≥70 2,096 (0.3) 72 (0.1) 26 (0.1) 
Tubal ligation at end of observation    
No 672,377 (91.6) 62,509 (79.5) 20,677 (81.0) 
Yes 61,455 (8.4) 16,085 (20.5) 4,839 (19.0) 
Parity at end of observation    
0 342,192 (46.6) 21,170 (26.9) 8,481 (33.2) 
1 62,582 (8.5) 6,272 (8.0) 2,176 (8.5) 
2 142,476 (19.4) 19,240 (24.5) 6,268 (24.6) 
≥3 186,582 (25.4) 31,912 (40.6) 8,591 (33.7) 
Endometriosis ‡    
No 713,013 (97.2) 59,725 (76.0) 16,334 (64.0) 
Yes 20,819 (2.8) 18,869 (24.0) 9,182 (36.0) 
Fibroids ‡    
No 721,137 (98.3) 54,977 (70.0) 14,421 (56.5) 
Yes 12,695 (1.7) 23,617 (30.0) 11,095 (43.5) 
Prolapse ‡    
No 715,643 (97.5) 46,408 (59.0) 20,139 (78.9) 
Yes 18,189 (2.5) 32,186 (41.0) 5,377 (21.1) 
Socio-economic disadvantage score 
(SEIFA§) quintile at study entry || 
   
1 (most disadvantaged) 122,758 (16.7) 14,213 (18.1) 4,590 (18.0) 
2 160,028 (21.8) 21,514 (27.4) 6,364 (24.9) 
3 98,783 (13.5) 9,912 (12.6) 3,202 (12.5) 
4 118,065 (16.1) 10,863 (13.8) 3,577 (14.0) 
5 (least disadvantaged) 232,575 (31.7) 21,847 (27.8) 7,722 (30.3) 
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Remoteness at study entry ||    
Major cities 548,088 (74.7) 55,110 (70.1) 19,248 (75.4) 
Inner regional 63,417 (8.6) 7,880 (10.0) 2,108 (8.3) 
Outer regional 63,584 (8.7) 8,811 (11.2) 2,074 (8.1) 
Remote 36,015 (4.9) 4,295 (5.5) 1,212 (4.7) 
Very remote 16,772 (2.3) 1,423 (1.8) 511 (2.0) 
* These women had a hysterectomy for benign indications before their study exit (their hysterectomies occurred either before their first electoral record, or 
during the study window) and therefore contribute exposed time to the analysis. Women whose hysterectomy was performed during the study window 
contribute both unexposed and exposed time. 
† These women had a hysterectomy but contribute only unexposed time to the analysis as their hysterectomy occurred at, or after, their study exit (these 
women predominantly exited due to a bilateral/unilateral oophorectomy performed prior to, or at the time of, their hysterectomy), or was performed for a 
non-benign indication (n=4632; at which time follow-up was censored if the woman had not already exited the study). 
‡ Condition included as a diagnosis during any hospitalisations 1970-2015. 
§ Socio-Economic Indexes for Areas. 
|| Percentages do not add to 100% due to a small proportion of missing data. 
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Table 2: Association between hysterectomy for a benign indication and invasive epithelial ovarian cancer, by histologic subtype*  
Adjustment models† 
All invasive ovarian cancer 
HR (95% CI) 
Serous 
HR (95% CI) 
Mucinous 
HR (95% CI) 
Endometrioid 
HR (95% CI) 
Clear cell 
HR (95% CI) 
Adjustment 1      
No hysterectomy 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Hysterectomy‡ 0.98 (0.85 to 1.11) 1.05 (0.89 to 1.23) 0.55 (0.28 to 1.06) 0.69 (0.41 to 1.18) 0.56 (0.27 to 1.16) 
Adjustment 2      
No hysterectomy 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Hysterectomy‡ 0.65 (0.56 to 0.75) 0.76 (0.63 to 0.91) 0.38 (0.19 to 0.75) 0.30 (0.17 to 0.52) 0.19 (0.09 to 0.41) 
* Time was censored at hysterectomy for malignancy. Hysterectomy is time-varying. Ovarian cancer includes primary ovarian, fallopian tube, and peritoneal 
cancer. For each histologic subtype analysis, follow-up time is censored at diagnosis of other subtypes. HR = hazard ratio; CI = confidence interval. 
† Models were stratified by decade of birth and adjusted for age at study entry, tubal ligation (yes/no), and parity (3 or more vs 0-2 births) (Adjustment 1), and 
additionally endometriosis (yes/no) and fibroids (yes/no) (Adjustment 2). Adjusting for genital prolapse (a third common indication for hysterectomy) did not 
affect the association between hysterectomy and ovarian cancer, so this was not included in presented models. 
‡ As hysterectomy is time-varying, the analysis compares exposed time (‘hysterectomy’, contributed by women after their hysterectomy) vs unexposed time (‘no 
hysterectomy’, contributed by women before their hysterectomy and by women who did not have a recorded hysterectomy). We assigned date of hysterectomy 
as date of hospital discharge. For the vast majority (99.9%) of the women in this analysis, admission and discharge dates for hospitalisation for hysterectomy 
were identical (78.9%) or only one month apart (21.0%), because recovery in hospital after hysterectomy is typically short and the provided HMDC data 
included admission/discharge month and year (not day). 
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Table 3: Association between hysterectomy for a benign indication and invasive 
epithelial ovarian cancer*, by indication  
Recorded hysterectomy indication HR (95% CI)† 
No hysterectomy 1.00 (Reference) 
Hysterectomy performed for: ‡  
Endometriosis (not fibroids or prolapse) 1.18 (0.71 to 1.96) 
Fibroids (not endometriosis or prolapse) 1.10 (0.79 to 1.55) 
Prolapse (not endometriosis or fibroids) 0.89 (0.67 to 1.18) 
Fibroids and endometriosis (not prolapse) 0.80 (0.43 to 1.50) 
Prolapse and endometriosis (not fibroids) 0.71 (0.32 to 1.58) 
Prolapse and fibroids (not endometriosis) 1.16 (0.70 to 1.93) 
Prolapse, fibroids and endometriosis 0.77 (0.32 to 1.85) 
Other indications 0.98 (0.82 to 1.18) 
*  Time was censored at hysterectomy for malignancy. Hysterectomy is time-varying. Ovarian 
cancer includes primary ovarian, fallopian tube, and peritoneal cancer.  
† Models were stratified by decade of birth and adjusted for age at study entry, tubal ligation 
(yes/no), and parity (3 or more vs 0-2 births). HR = hazard ratio; CI = confidence interval. 
‡ We created a single time-varying variable for hysterectomy by indication. We defined indication 
using codes recorded in any of the diagnosis fields at the time of surgery, in order to capture the 
pathological context of the surgery as completely as possible. Women who had a hysterectomy 
before study exit contribute exposed time to one of the indication categories from their 
hysterectomy onwards. For each of the following categories, other conditions, such as those coded 
as uterine disorders or disorders of menstruation, may have been also noted in the hospital record. 
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Table 4: Association between hysterectomy for a benign indication and invasive 
epithelial ovarian cancer*, by presence of endometriosis, fibroids, and prolapse†  
Hysterectomy by presence of benign 
gynaecological conditions 
HR (95% CI)‡ 
Women with endometriosis  
No hysterectomy 1.00 (Reference) 
Hysterectomy 0.17 (0.12 to 0.24) 
Women without endometriosis  
No hysterectomy 1.00 (Reference) 
Hysterectomy 1.09 (0.95 to 1.26) 
Women with fibroids  
No hysterectomy 1.00 (Reference) 
Hysterectomy 0.27 (0.20 to 0.36) 
Women without fibroids  
No hysterectomy 1.00 (Reference) 
Hysterectomy 1.09 (0.94 to 1.27) 
Women with endometriosis or fibroids  
No hysterectomy 1.00 (Reference) 
Hysterectomy 0.26 (0.21 to 0.33) 
Women without endometriosis or fibroids  
No hysterectomy 1.00 (Reference) 
Hysterectomy 1.15 (0.98 to 1.35) 
Women with prolapse  
No hysterectomy 1.00 (Reference) 
Hysterectomy 1.24 (0.91 to 1.69) 
Women without prolapse  
No hysterectomy 1.00 (Reference) 
Hysterectomy 0.97 (0.83 to 1.15) 
* Time was censored at hysterectomy for malignancy. Hysterectomy is time-varying. Ovarian 
cancer includes primary ovarian, fallopian tube, and peritoneal cancer.  
† Strata (presence/absence of each condition) are defined by whether the condition was included 
as a diagnosis during any hospitalisations 1970-2015. 
‡ Models were stratified by decade of birth and adjusted for age at study entry, tubal ligation 
(yes/no), and parity (3 or more vs 0-2 births). HR = hazard ratio; CI = confidence interval. 
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Figure legend 
Figure 1: Association between hysterectomy for a benign indication and invasive 
epithelial ovarian cancer, by (A) period of hysterectomy and (B) age at hysterectomy, 
compared to no hysterectomy.  Time was censored at hysterectomy for malignancy. 
Hysterectomy is time-varying. Ovarian cancer includes primary ovarian, fallopian tube, and 
peritoneal cancer. Models were stratified by decade of birth and adjusted for age at study 
entry, tubal ligation (yes/no), and parity (3 or more vs 0-2 births). In B, patterns were similar 
if we assigned birthdate at the electoral birth-year band midpoint.  
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